Company ProfilePremium

Starpharma Holdings Limited

Company Profile Analysis

Ticker: SPL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Starpharma Holdings Limited - Company showcase

Year Founded & Workforce

1996

Starpharma Holdings Limited logo

Starpharma Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Starpharma Holdings Limited Overview

Starpharma is a small-cap Melbourne biotechnology company that has spent roughly three decades building what it describes as the world's leading proprietary position in dendrimers — precisely engineered, highly branched nanoscale polymers that can be loaded with drugs, targeting groups and radionuclides. Its commercial engine is the DEP® (Dendrimer Enhanced Product) platform, which conjugates existing or novel drugs to dendrimers to improve solubility, pharmacokinetics, tumour targeting and tolerability. After a difficult 2023 — the loss of AstraZeneca's AZD0466 program and termination of the Mundipharma VivaGel® BV licence — the company was restructured under CEO Cheryl Maley around a "platform plus partnerships" model. That pivot has been validated by a September 2025 Genentech (Roche) licence (US$5.5M upfront, up to US$564M milestones), a Radiopharm Theranostics option deal, and the Medicxi-backed Petalion venture. Its lead internal asset, DEP® HER2-Lutetium, is scheduled to enter a European first-in-human trial in H2 CY2026, funded by an A$32M entitlement offer.


Company's own description. In its FY2025 and FY2026 ASX releases, Starpharma describes itself as an innovative biotechnology company with two decades of experience advancing dendrimer technology from laboratory to patient. Its stated portfolio comprises clinical-stage DEP® assets, preclinical radiopharmaceutical programs, partnered research collaborations, and three over-the-counter (OTC) marketed products (VIRALEZE™, VivaGel® BV and the VivaGel® condom). In the FY2026 results (26 August 2026), management framed the core strategy as building long-term shareholder value through a pipeline of targeted oncology therapies enabled by DEP® technology.

What the company actually does. Starpharma operates three economically distinct activities under one corporate roof:

  1. DEP® platform partnering (licensing/research services). Starpharma designs and synthesises dendrimer-drug conjugates incorporating partners' molecules. Revenue arrives as upfront licence fees, research/FTE fees, option fees, development and commercial milestones, and royalties. Current counterparties: Genentech (Roche), Radiopharm Theranostics, Petalion Therapeutics (Medicxi-backed, 22.5% Starpharma-owned), with historical/legacy arrangements with AstraZeneca, MSD (Merck & Co.) and Chase Sun (China).

  2. Internal DEP® drug development. Starpharma self-funds early clinical assets to the point of partnering: DEP® HER2-Lutetium (lead radioligand therapy, preclinical → Phase 1), DEP® SN38 and DEP® cabazitaxel ("partner-ready" Phase 2 assets), DEP® docetaxel (Phase 2 completed), plus preclinical DEP® HER2-Zirconium (imaging), DEP® ADCs and DEP® gemcitabine.

  3. Marketed OTC products based on SPL7013 (astodrimer sodium). VIRALEZE™ antiviral nasal spray, VivaGel® BV (marketed as Fleurstat BVgel in Australia/NZ by Aspen; formerly Betadine BV via Mundipharma) and the VivaGel® condom (Ansell/LifeStyles Dual Protect in Australia; Okamoto in Japan). These are sold through distributors under supply agreements, with Starpharma manufacturing (via contract manufacturers) and supplying product.

Revenue model mix (independent characterisation, FY2026). Of A$12.0M FY2026 revenue, A$8.3M (~69%) was the one-off Genentech upfront licence payment; the balance (~A$3.7M, ~31%) comprised product sales (VIRALEZE™, VivaGel® BV), royalties, Petalion research revenue and other licence/research income (FY2026 Annual Report release, 26 August 2026). The exact split among product, royalty and research income is not publicly disclosed in the reviewed summaries. In FY2025 (A$4.9M) revenue was driven by Petalion research income and higher VIRALEZE™/VivaGel® BV sales (FY2025 results release, 26 August 2025). There is no subscription revenue.

Value-chain position. Starpharma sits at the discovery/early-development end of the pharmaceutical value chain: platform chemistry, conjugate design, preclinical pharmacology, GMP dendrimer manufacture (outsourced) and early clinical proof-of-concept. It does not own commercial-scale manufacturing or a sales force. Late-stage development and commercialisation are intended to be carried by licensees.

Customer types and end-markets. (i) Large pharma/biotech oncology developers (Genentech/Roche); (ii) radiopharmaceutical developers (Radiopharm Theranostics); (iii) venture-backed asset-centric companies (Petalion); (iv) consumer health/pharmacy distributors (ITROM in MENA, Aspen in ANZ, Hengan in Hong Kong/Macau, others for VIRALEZE™). End-markets: oncology (HER2-positive gastric/GEJ and breast cancer; ovarian, prostate, colorectal and other solid tumours), radiopharmaceuticals, women's health (bacterial vaginosis), respiratory antiviral prophylaxis, sexual health.

Strategy

Stated strategic themes (FY2025–FY2026 Annual Reports, quarterlies and CEO commentary, paraphrased).

  1. Maximise value of DEP® assets — prioritise high-impact programs and out-license the clinical-stage DEP® SN38 and DEP® cabazitaxel.

  2. Accelerate early asset development — especially radiopharmaceuticals, led by DEP® HER2-Lu into the clinic in H2 CY2026.

  3. Build new high-impact partnerships that unlock the DEP® platform — Genentech, Radiopharm, Petalion, and the Star Navigator program for rapid partner evaluation.

  4. Build long-term sustainability — grow revenue from collaborations, licensing and product sales while managing costs.

  5. Strengthen intellectual property — new patent filings (radioligand therapy application filed July 2026; additional AU dendrimer and targeted-conjugate applications in March and July 2026 per PitchBook).

The CEO's January 2026 quarterly set out 2026 priorities as moving the radiotheranostic program into the clinic, executing priority partnerships (Genentech, Petalion, Radiopharm), and adding new partnering opportunities via Star Navigator.

Initiatives in the last 24 months.

ESG commitments. No quantified emissions or sustainability targets identified.

Medium-term financial targets/guidance. Starpharma does not issue revenue or earnings guidance. The only forward financial statement is the cash runway "into FY28" (July and August 2026). Company presentation materials (July 2026) suggested DEP® HER2-Lu could be Phase 2/3-ready by 2028 and may qualify for accelerated pathways.

Products & Services

5A. DEP® Platform (technology offering to partners)

AttributeDetail
DescriptionProprietary dendrimer scaffold to which drug payloads, targeting moieties (e.g., HER2 binders), PEG and/or chelators for radionuclides are attached in defined ratios
Claimed capabilitiesImproved solubility (removing toxic excipients such as polysorbate 80), extended circulation and pharmacokinetic control, enhanced tumour accumulation, reduced off-target toxicity (e.g., reduced bone-marrow toxicity and hair loss reported in DEP® docetaxel/cabazitaxel studies), multiple payloads per carrier
Applicable payload classesSmall molecules, chemotherapeutics, peptides, proteins, radionuclides (radiotheranostics), antibody-drug conjugates
Clinical validationCompany states more than 350 patients have been treated with DEP® products across its three internal Phase 2 programs (FY2024 Annual Report) plus AstraZeneca's AZD0466 trial
Partner-access vehicle"Star Navigator" — a rapid-assessment program in which Starpharma generates exploratory dendrimer conjugates of a partner's molecule to test fit with DEP®; Radiopharm was the first Star Navigator deal (Sept 2025)
Pricing modelUpfront fees, research/FTE fees, option fees, milestones, royalties (deal-specific)

5B. Internal DEP® Pipeline — product by product

AssetMechanism / descriptionTarget indication(s)Stage (Oct 2026)Latest status
DEP® HER2-Lutetium (DEP® HER2-Lu / "DEP® HER2")HER2-receptor-targeting dendrimer conjugate carrying a lutetium-177 radionuclide payload (radioligand therapy)Locally advanced/metastatic HER2-overexpressing gastric and gastro-oesophageal junction cancer and other HER2-expressing cancers after prior HER2 therapyPreclinical package complete; Phase 1 planned H2 CY2026 (Europe, up to 15 patients)FDA Type C feedback supportive (21 April 2026); GMP precursor dendrimer manufactured; clinical sites selected; preclinical data (July 2026) showed favourable biodistribution with high tumour uptake and low kidney accumulation; company-reported survival benefit vs. Enhertu in a high-HER2 model (50% vs 12.5% at day 57, per company presentation summarised by FilingReader)
DEP® HER2-ZirconiumHER2-targeted dendrimer carrying zirconium-89 for PET imaging (theranostic companion)Imaging of HER2+ breast/gastric cancersPreclinicalPreviously planned for first-in-human imaging trial; superseded in priority by HER2-Lu therapy
DEP® SN38 (formerly referred to as DEP® irinotecan)Dendrimer conjugate of SN38, the active metabolite of irinotecanPlatinum-resistant ovarian cancer (PROC), colorectal, pancreatic and other solid tumoursPhase 2 completed (monotherapy and combination with 5-FU/leucovorin)Positive FDA feedback on PROC pathway (Dec 2024); "partner-ready"; out-licensing slower than anticipated (Edison, Aug 2026)
DEP® cabazitaxelDetergent-free dendrimer formulation of cabazitaxelMetastatic castration-resistant prostate cancer and other cancersPhase 2 completedPositive Phase 2 results (Oct 2023); "partner-ready"; seeking licensee
DEP® docetaxelDetergent-free dendrimer formulation of docetaxelVarious solid tumours (monotherapy and combinations)Phase 2 completedClinical validation of platform; not currently a priority
DEP® ADCs (incl. HER2-targeted DEP® SN38 ADC)Dendrimer-based antibody/targeting conjugates with high drug-to-carrier ratiosHER2+ cancers (ovarian model data)PreclinicalFeeds next-generation targeted DEP® candidates
DEP® gemcitabineDendrimer-gemcitabine conjugatePancreatic and other cancersPreclinicalEarlier "excellent" preclinical data (2019 era); lower priority
Next-generation targeted DEP® oncology assetsUnnamed new targeted conjugatesOncologyDiscovery/preclinicalTo be accelerated with entitlement-offer proceeds

5C. Partnered DEP® Programs

ProgramPartnerStatus
Genentech DEP® conjugates incorporating Genentech medicines for selected oncology targetsGenentech (Roche)Active; exclusive worldwide licence; Starpharma conducting agreed work
Radiopharmaceutical dendrimer-drug conjugate incorporating Radiopharm moleculeRadiopharm Theranostics (ASX: RAD; Nasdaq: RADX)Option period began July 2026; up to A$91M if exercised
Targeted dendrimer-drug conjugate oncology candidatePetalion Therapeutics (Medicxi)Active; Starpharma provides fee-for-service R&D; holds 22.5% equity
AZD0466 (DEP® Bcl2/xL inhibitor)AstraZenecaDiscontinued by AZ (July 2023); licence remains in effect
DEP® version of a major marketed AZ oncology drugAstraZeneca (Development & Option Agreement, FY2019)Status not publicly updated in recent filings
DEP® research programsMSD (Merck & Co.)Historical; current status not publicly disclosed
DEP® anti-infectiveChase Sun (China)Historical; current status not publicly disclosed

5D. Marketed Products (SPL7013 / astodrimer sodium)

ProductDescriptionTarget customerRegulatory / launchCommercial model
VIRALEZE™ antiviral nasal sprayNasal spray containing astodrimer sodium; non-clinical data show virucidal activity (>99.9% inactivation of SARS-CoV-2 in lab testing) and minimal systemic absorptionConsumers seeking respiratory-virus barrier protectionRegistered as a medical device in 30–35+ countries (UK, EU and others); launched 2020–21; not approved in AustraliaDistributors (e.g., Vietnam, Saudi Arabia via Etqan & Nazahah, Italy via ADMENTA/LloydsFarmacia, Hong Kong/Macau via Hengan, Indonesia registration Dec 2022); online sales in certain markets
VivaGel® BVNon-antibiotic vaginal gel for treatment of bacterial vaginosis (BV) and prevention of recurrent BVWomen 15–44 (BV is the most common vaginal condition in this group)Registered in 50–55+ countries incl. Australia, NZ, UK, Europe, Asia, MENA; marketed as Fleurstat BVgel (Aspen, ANZ); formerly Betadine BV (Mundipharma, rights reverted Aug 2023)Starpharma manufactures and supplies; distributors sell (ITROM in 13 MENA countries, 7-year term from Jan 2024); European distribution expansion discussions ongoing (Q4 FY2026)
VivaGel® condomCondom with SPL7013-containing lubricantSexual health consumersLaunched in Australia (LifeStyles Dual Protect, Ansell); approved in Japan (Okamoto) and other marketsLicensing/supply; small royalty/product income

Financial Narrative

6A. Income Statement

Sources and derivations: Revenue FY2022–FY2025 from Stockopedia financial summary consistent with company releases (FY2024 A$9.8M and FY2025 A$4.9M confirmed in FY2024/FY2025 releases; FY2026 A$12.05M per MarketScreener, A$12.0M per company). FY2021 revenue was A$2.15M (Stockopedia). FY2024 reported loss derived as the company's underlying loss of A$14.7M less the A$6.55M Mundipharma settlement; FY2025 loss A$10.0M (company; A$9.99M MarketScreener); FY2026 loss A$7.5M (company; A$7.47M MarketScreener). FY2026 underlying loss derived as reported loss less A$8.34M Genentech upfront. R&D: FY2024/FY2025 per FY2025 release; FY2026 per Edison (Aug 2026). StockAnalysis reports FY2026 revenue of A$12.67M and FY2025 A$5.85M, which likely include interest/other income — a definitional discrepancy.

Gross profit, operating income, EBITDA, pre-tax income. Starpharma does not present a gross profit line meaningful for analysis (its revenue is dominated by licence income with negligible cost of sales), and EBITDA is not a company-reported metric. Aggregator Craft shows H1 FY2026 gross profit of A$10.4M on revenue of A$10.8M and EBIT of A$1.0M — consistent with a high gross margin when licence income dominates. Full-year gross profit, EBITDA and pre-tax income for FY2022–FY2026 are therefore "not publicly disclosed" in a comparable form. Income tax is effectively nil (the company is loss-making and benefits from the Australian R&D Tax Incentive, which is recorded as other income/receivable — e.g., A$7.1M received Dec 2022, A$7.2M received Oct 2023, ~A$5.0M expected H1 FY2025).

6B. Half-Year Detail

Notes: H1 FY2024 revenue (A$9.76M shown here) is approximated: the H1 FY2025 Appendix 4D shows prior-period revenue of A$8.025M including the Mundipharma settlement and adjusted revenue of A$1.47M, while the FY2024 interim commentary cites adjusted revenue of A$3.2M; the figure in the table should therefore be read as indicative only. H1 FY2024 loss of A$1.03M included the settlement (A$7.59M excluding it). H1 FY2025 revenue was originally A$2.427M and later re-presented as A$1.888M. H1 FY2026: Appendix 4D, 18 February 2026. Implied H2 FY2026 loss ≈ A$8.8M (A$7.47M full-year loss + A$1.37M H1 profit).

Correction note on the H1 FY2024 row above: the most defensible primary figures are revenue A$8.03M (including settlement) and adjusted revenue A$1.47M (per H1 FY2025 4D). Readers charting this row should use 8.03 for H1FY2024 total revenue.

6C. Balance Sheet and Liquidity

Additional cash datapoints: 30 Sept 2023 A$35.6M; 31 Dec 2024 A$20.3M; 31 Dec 2025 ≈A$18.2M (Craft, aggregator); 31 March 2026 A$14.1M; 30 June 2026 A$11.0M; pro forma 30 June 2026 including entitlement offer A$44.5M (company, 15 July 2026). Net proceeds of ~A$30M were received in August 2026, so post-raise cash in Q1 FY2027 is likely in the low-to-mid A$40Ms before quarterly burn (Q1 FY2027 Appendix 4C, due late October 2026, will confirm).

TipRanks (aggregator, likely FY2025 basis) reports a current ratio of 4.32 and debt/equity of 3.68% (lease liabilities).

6D. Cash Flow: notes and sources

Notes: FY2025 and FY2026 operating cash flows per Edison (Aug 2026). Customer receipts rose by A$3.1M in FY2025 (Q4 FY2025 quarterly) and by 149% in FY2026 vs FY2025 (Q4 FY2026 quarterly). Q2 FY2026 customer receipts were A$9.1M including the Genentech upfront. Capex is immaterial for this asset-light model (laboratory equipment only). The A$32M gross (≈A$30M net) entitlement offer completed in August 2026 falls in FY2027. No buybacks or dividends have ever been paid.

6F. Commentary on trends, inflections and drivers

Revenue: Starpharma's revenue line is structurally lumpy. Three of the last five years were shaped by non-recurring items: the A$6.55M Mundipharma settlement in FY2024, the A$8.34M Genentech upfront in FY2026, and earlier COVID-era VIRALEZE™ launch sales in FY2022. Stripping these out, "base" revenue has hovered in the A$2–5M range. The genuine positive inflection is qualitative: FY2025 base revenue grew strongly as Petalion research fees and product sales rose, and FY2026 base revenue of ~A$3.7M was broadly maintained while the company was absorbing Genentech work. The analyst consensus (MarketScreener/Stockopedia) of FY2026E A$15.8M and FY2027E A$24M implies expectations of additional milestones or new deals; the FY2026 actual of A$12.05M fell short of the FY2026E consensus.

Cost base: R&D fell from A$10.1M (FY2024) to A$8.4M (FY2025) as the three DEP® Phase 2 trials completed, then rose to A$11.1M (FY2026) as DEP® HER2-Lu moved through IND-enabling work and GMP manufacture. Corporate and administration costs were cut (H1 FY2025 down A$0.5M year-on-year). Expect R&D to rise again in FY2027 as the Phase 1 HER2-Lu trial starts.

Losses and cash burn: The reported loss improved from A$10.0M (FY2025) to A$7.5M (FY2026), but this flatters the trajectory: excluding the Genentech upfront, the underlying loss widened to ~A$15.8M. Operating cash outflow improved to A$3.2M in FY2026 only because of the US$5.5M receipt. Underlying quarterly burn before partner receipts is approximately A$3–4M.

Balance sheet: Cash declined from A$35.2M (June 2023) to A$11.0M (June 2026) — roughly 3 years of runway consumed with no equity raised. The August 2026 raise reset the balance sheet to ~A$44.5M pro forma, which management says funds operations into FY2028.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (analytical)ContentsProducts / programs

DEP® Partnered Programs

Licensing, option and research-services income from third parties

Genentech licence; Radiopharm option; Petalion collaboration; legacy AstraZeneca licence; historical MSD and Chase Sun work

DEP® Internal Pipeline

Self-funded drug candidates (cost centre; no revenue until out-licensed)

DEP® HER2-Lu, DEP® HER2-Zr, DEP® SN38, DEP® cabazitaxel, DEP® docetaxel, DEP® ADCs, DEP® gemcitabine

Marketed Products (SPL7013)

OTC products sold via distributors

VIRALEZE™, VivaGel® BV, VivaGel® condom

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Total revenue as reported (AUD Mn)

9.764.9112.05

One-off licence/settlement income (AUD Mn)

6.5508.34

Revenue excluding one-offs (AUD Mn)

3.214.913.71

One-off share of total revenue (%)

67069

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

4.904.219.764.9112.05

Revenue growth YoY (%)

128-14132-50145

Research and product development expense (AUD Mn)

——10.108.4011.10

Net profit/(loss) after tax (AUD Mn)

——-8.10-9.99-7.47

Underlying net loss excl. one-offs (AUD Mn)

——-14.70-9.99-15.81

Basic EPS (AUD)

——-0.02-0.02-0.02

Diluted EPS (AUD)

——-0.02-0.02-0.02

Dividends per share (AUD)

00000

Net margin (%)

——-83-203-62

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricH1FY2024H1FY2025H1FY2026

Revenue (AUD Mn)

9.762.4310.83

Revenue excl. one-offs (AUD Mn)

3.202.432.49

Profit/(loss) for half (AUD Mn)

-1.03-5.391.37

R&D expense (AUD Mn)

—4.344.95

Key Financials and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents at 30 June (AUD Mn)

—35.2—15.411.0

Total borrowings (AUD Mn)

00000

Net cash (AUD Mn)

—35.2—15.411.0

Shares on issue (M)

———418.2421.0

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Net operating cash flow (AUD Mn)

———-6.8-3.2

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Equity raised (AUD Mn)

00000

Financial Analysis

RatioValueBasis / comment

ROE

Negative (TipRanks: -53%)

Aggregator, likely FY2025; loss-making

ROA

Negative

Loss-making

ROIC

Negative (TipRanks: -9.15%)

Aggregator

Current ratio

4.32x

Aggregator; pro forma post-raise substantially higher

Debt/Equity

~0.04x

Leases only

Revenue CAGR FY2022–FY2026

≈25%

(12.05/4.90)^(1/4) − 1, derived; heavily distorted by one-offs

R&D intensity FY2026

92% of revenue

11.1/12.05

Geographic Revenue

Region (counterparty domicile)FY2024FY2025

Region

Principal FY2026 revenue sources (qualitative)

Direction

United States

Genentech upfront (A$8.3M) — the single largest FY2026 item

Sharply up in FY2026; future milestones uncertain

United Kingdom / Europe

Petalion (UK) research fees; VIRALEZE™ and VivaGel® BV distributor sales (UK/EU); former Mundipharma Europe income lost after 2023

Petalion growing; VivaGel® BV Europe in re-partnering phase

Australia / NZ

Aspen (Fleurstat BVgel) supply/royalty; LifeStyles Dual Protect condom; Radiopharm (Australian counterparty) option fee from FY2027

Stable/small

Asia

VIRALEZE™ distributors (Vietnam, Hong Kong/Macau, Indonesia); Okamoto (Japan) condom

Small; COVID-era tailwind faded

MENA

ITROM VivaGel® BV (13 countries; sales expected from FY2025) and VIRALEZE™ in Saudi Arabia

Emerging

Valuation Snapshot

MetricValueSource

Last price (ASX)

A$0.85 (12 Oct 2026)

ListCorp

52-week range

A$0.23 – A$0.86

StockAnalysis (30 Sept 2026)

1-year performance

+500% to late August 2026; ~+365% at an earlier 2026 reading

Motley Fool Australia

2026 YTD (ADR SPHRY)

+140.7% to 1 Oct 2026 (ADR US$5.85)

Macrotrends

Shares on issue

~477.05M

TipRanks; ASX allotment

Market capitalisation

≈A$405M

Derived

Beta

0.76

StockAnalysis

Valuation Multiples

MultipleStarpharmaComment

EV (AUD Mn)

≈360

Market cap ~405 less ~44.5 pro forma cash

EV/Sales (FY2026)

≈30x

360 / 12.05

EV/Sales excl. one-offs

≈97x

360 / 3.71

Capital Markets

ItemDetail

Consensus target price

A$1.25 (MarketScreener/Stockopedia), ~47% above A$0.85; coverage is thin

Consensus revenue

FY2026E A$15.8M (actual A$12.05M); FY2027E A$24M (Stockopedia)

Sponsored research

Edison Group (Arron Aatkar, PhD) publishes company-sponsored research

Other

Simply Wall St cites coverage by up to 9 analysts (likely overstated/aggregated)

Dividend history

No dividends ever paid; none expected while in development stage

Dividend policy

Retain funds for R&D

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

No financial debt; lease liabilities only

Share Price & Returns

DateTypeSizePriceDiscount

Jul–Aug 2026

1-for-7.5 renounceable entitlement offer (fully underwritten by Canaccord Genuity)

56.13M shares; ~A$32M gross / ~A$30M net

A$0.57

25% to last close of A$0.76

Analyst Conclusions

22A. Management guidance

Management does not issue revenue/earnings guidance. Stated expectations: DEP® HER2-Lu first-in-human Phase 1 in Europe beginning H2 CY2026 (up to 15 patients; safety, tolerability, PK, biodistribution, dosimetry); initial data H1 CY2027 (per company presentation as reported); Phase 2/3 readiness by 2028; continued execution of the Genentech, Radiopharm and Petalion programs; continued efforts to out-license DEP® SN38 and DEP® cabazitaxel; cash runway into FY2028.

22B. Consensus expectations

Thin consensus shows FY2027E revenue of ~A$24M (Stockopedia), which would require new milestone or licence income well above FY2026's A$12.05M. Consensus target price A$1.25.

22C. Bull case

  1. Platform validated at the highest level. Genentech's exclusive, multi-target licence (US$564M milestones plus royalties) — following three years of joint work — suggests DEP® is now a credible pharma-grade technology, raising the probability of additional big-pharma deals.

  2. Radiopharma is a seller's market. Pharma demand for RLT assets is intense; positive human biodistribution data from DEP® HER2-Lu in H1 CY2027 could trigger a licensing transaction worth multiples of the current ~A$360M EV, especially given FDA-acknowledged unmet need and potential Fast Track.

  3. Funded and de-risked balance sheet. ~A$44.5M pro forma cash, no debt and runway into FY2028 mean the next value-inflection (Phase 1 data) is fully funded, while Radiopharm (up to A$91M) and Genentech milestones provide non-dilutive upside.

22D. Bear case

  1. Revenue is mostly one-off. Base revenue of ~A$3.7M has barely grown; the ~A$15.8M underlying loss in FY2026 means the company is still structurally burning cash, and EV/base-sales near 100x leaves no margin for error.

  2. Partner track record is mixed. AstraZeneca discontinued AZD0466; Phase 2 assets SN38 and cabazitaxel remain unlicensed years after positive data. Genentech could similarly deprioritise programs, with milestones remaining theoretical.

  3. Single-asset preclinical bet after a 5–8x re-rating. DEP® HER2-Lu has no human data, faces formidable HER2 incumbents (Enhertu) and RLT competitors, and any delay in trial start or a disappointing biodistribution readout could reverse much of the 2025–26 gain; further dilution is likely before Phase 2.

22E. Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Late October 2026Q1 FY2027 Appendix 4C — post-raise cash, burn rate, Phase 1 start status
November 20262026 AGM — remuneration vote, director re-elections
H2 CY2026First patient dosed in DEP® HER2-Lu Phase 1 (Europe)
FY2027Radiopharm decision to exercise exclusive licence option (up to A$91M)
FY2027Any Genentech development milestone or target nomination
FY2027Out-licensing of DEP® SN38 and/or DEP® cabazitaxel
FY2027New Star Navigator partnerships; Petalion progress/funding tranches
February 2027H1 FY2027 results (scheduled ~22 February 2027 per Stockopedia)
H1 CY2027Initial DEP® HER2-Lu imaging/safety/dosimetry data
OngoingVivaGel® BV European distribution deal; substantial-holder movements

22F. Analyst verdict

Starpharma has executed one of the more striking turnarounds on the ASX biotech board. Two years ago it was a cash-burning platform company whose flagship partnership (AstraZeneca's AZD0466) had been cancelled, whose consumer products had lost their main licensee, and whose market value had sunk below A$40M. Under Cheryl Maley, management narrowed the strategy to what the dendrimer platform does best — targeted oncology delivery and radiopharmaceuticals — and monetised it through partners. The September 2025 Genentech licence was the pivotal proof point, and the subsequent Radiopharm option, FDA alignment on DEP® HER2-Lu, and an almost fully subscribed A$32M raise have given the company the credibility and cash it lacked.

The investment case is now binary in character and back-ended in timing. At roughly A$405M market capitalisation and ~A$360M enterprise value, the market is ascribing substantial value to a preclinical radioligand therapy and to undisclosed Genentech milestones, against a recurring revenue base of under A$4M and an underlying annual loss approaching A$16M. The financials themselves offer limited support: FY2026's headline improvement was driven by a single upfront payment, and the out-licensing of the two Phase 2 assets — management's top priority a year ago — remains unfinished.

On balance, Starpharma screens as a well-funded, partner-validated, high-risk development story whose next 12–18 months contain genuine value-inflection points: first patient dosing in H2 CY2026, possible Radiopharm option exercise, and first human HER2-Lu data in H1 CY2027. Investors who believe dendrimer biodistribution advantages will translate into humans have a funded path to that answer; those who weight the company's history of partner attrition and slow licensing should recognise that the share price already discounts considerable success. The verdict: constructive on platform credibility and execution momentum, but position-sizing should reflect single-asset clinical risk, thin analyst coverage and a valuation that has run well ahead of fundamentals.


Principal sources consulted

Starpharma ASX announcements: FY2024 Appendix 4E (22 Aug 2024); H1 FY2025 Appendix 4D (26 Feb 2025); FY2025 Results & Annual Report (26 Aug 2025); Genentech licence (22 Sept 2025) and upfront receipt (22 Oct 2025); Radiopharm agreement (30 Sept 2025) and option fee (3 July 2026); 2025 AGM Notice and Results; Quarterly 4Cs (Jan, Apr, Jul 2026); H1 FY2026 Appendix 4D (18 Feb 2026); FDA Type C release (21 Apr 2026); Entitlement Offer announcement, booklet and completion (15 Jul, 17 Jul, 11 Aug 2026); FY2026 Annual Report (26 Aug 2026); historical releases (Mundipharma settlement 14 Aug 2023; Petalion 8 Apr 2024; ITROM 22 Jan 2024; board appointments 2022–2023; CEO retirement 9 Jun 2023; Chair succession 13 Jun 2014). Radiopharm Theranostics ASX release (30 Sept 2025). Clarity Pharmaceuticals ASX release (16 Jan 2024). Edison Group Sparks note (Aug 2026). Biotech Dispatch, BioSpectrum Asia, BioMelbourne, Motley Fool Australia, Kalkine, InvestSMART, ListCorp, FilingReader. Aggregators (flagged where used): MarketScreener, StockAnalysis, Stockopedia, TipRanks, Simply Wall St, PitchBook, Craft, Revelio Labs, Macrotrends, Investing.com.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / prior rolesEducation

Cheryl Maley

Chief Executive Officer & Managing Director

Since 8 January 2024

Former NED of Clarity Pharmaceuticals (resigned to join Starpharma); extensive pharma commercial leadership background

B.Sc, DipEd, MBA, GAICD

VP Business Development

Business development lead (Star Navigator, partnering)

———

CFO / Company Secretary

Finance and secretariat

—

Not publicly verified

—

Chief Scientific / R&D leadership

Dendrimer chemistry and DEP® development

—

Long-tenured scientific staff (historical profiles reference DEP® docetaxel and NIH-funded programs)

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedIndependenceBackground

Rob Thomas AO

Non-executive Chair

Board Dec 2013; Chair 13 June 2014

Independent

Financial services career; former Lead Independent Director of Clarity Pharmaceuticals (resigned effective 23 Aug 2024 to concentrate on Starpharma); B.Ec (Monash); age ~78 (Investing.com)

Cheryl Maley

Managing Director & CEO

January 2024

Executive

See above

Lynda Cheng

Independent NED

1 August 2021

Independent

Chair of the Audit & Risk Committee (succeeded Zita Peach role on committee changes from Nov 2022 per company release)

Dr Jeff Davies

Independent NED

1 April 2022

Independent

30+ years at CSL (EVP & GM Asia-Pacific; Global Head Plasma Product R&D, CSL Behring); founding director, Centre for Biopharmaceutical Excellence; PhD Biochemistry (Monash); age ~67

Dr Russell Basser

Independent NED

20 February 2023

Independent

Medical oncologist; 21 years at CSL; founding member of CSL Seqirus leadership as SVP R&D (2015–2022); former Royal Melbourne Hospital oncologist

David McIntyre

NED (per Investing.com, appointed 2020)

2020

Independent

—

Dr Jackie Fairley

Former CEO (2006–2024)

——

Listed as advisor to the Board on some aggregators following retirement

Directors' Remuneration

MetricFY2025

CEO total remuneration (AUD K)

942.3

CEO salary component (AUD K)

498

CEO salary share of total (%)

52.8

CEO variable/equity share (%)

47.2

Major Shareholders

HolderStakeStatus / date

UIL Limited

Reduced from 8.02% to 6.39% (date ~2024–2025)

—

UBS Group AG

Became substantial ~19 June 2026; ceased 17 July 2026

Ceased (Form 605, 21 July 2026)

Unnamed new substantial holders

"Becoming a substantial holder" notices on 3 March, 15 April, 17 June, 23 June and 24 August 2026; "Change in substantial holding" 7 October 2026

—

Directors and CEO

CEO ~0.03% (Simply Wall St); directors hold small direct/indirect stakes

Insider ownership low (<1%)

Retail investors

Majority of register (typical of ASX small-cap biotech)

Not publicly quantified

Competitive Landscape

Competitors by Segment

Business lineCompetitorTypeRelative positioning

Dendrimer / nanocarrier drug delivery

Ashvattha Therapeutics (US, private)

Hydroxyl-dendrimer therapeutics (Johns Hopkins-derived)

Most direct dendrimer peer; clinical-stage in ophthalmology/neuroinflammation

Nanocarrier drug delivery

Cristal Therapeutics (NL, private)

CriPec polymeric micelles

Similar "platform improves known drugs" proposition

Nanocarrier / radio-enhancement

Nanobiotix (Euronext/Nasdaq)

Hafnium oxide nanoparticles (radio-enhancer), J&J licence

Larger, later-stage; named by PitchBook as a competitor

Conjugate platforms

Bicycle Therapeutics (Nasdaq)

Bicyclic peptide toxin and radio-conjugates

Competes for pharma partnering budgets in targeted delivery

Radiopharmaceuticals

Telix Pharmaceuticals (ASX: TLX)

Commercial-stage radiopharma

Far larger; competes for capital, sites and isotope supply

Radiopharmaceuticals

Clarity Pharmaceuticals (ASX: CU6)

Copper-isotope theranostics

Clinical-stage ASX peer; shared board/management heritage (Thomas, Maley)

Radiopharmaceuticals

Radiopharm Theranostics (ASX: RAD)

Clinical-stage RLT

Partner and potential competitor

HER2-targeted therapy (standard of care)

AstraZeneca/Daiichi Sankyo (Enhertu)

HER2 ADC

Benchmark comparator in Starpharma's preclinical data

HER2-targeted therapy

Roche (Herceptin, Kadcyla, Phesgo); Jazz/Zymeworks (zanidatamab)

HER2 antibodies/ADC/bispecific

Incumbent HER2 franchises

Bacterial vaginosis

Organon/Daré (Xaciato clindamycin gel); Lupin (Solosec secnidazole); generic metronidazole/clindamycin

Antibiotic BV treatments

VivaGel® BV differentiated as non-antibiotic

Antiviral nasal sprays

Marinomed (Carragelose-based sprays); SaNOtize (Enovid/VirX nitric-oxide spray); Taffix

OTC barrier/antiviral sprays

Fragmented, low-barrier category

Peer Comparison FY2024

MetricStarpharma (SPL)Telix (TLX)Clarity (CU6)Radiopharm (RAD)

Latest FY revenue

A$12.0M (FY2026)

~A$783M (FY2024, commercial products)

Pre-revenue (grant/R&D incentive only)

Pre-revenue

Revenue growth

+145%

Strong double-digit

n/m

n/m

Profitability

Net loss A$7.5M

Profitable at operating level (FY2024)

Loss-making

Loss-making

R&D intensity

~92% of revenue

Low % of revenue

Not meaningful

Not meaningful

Stage of lead asset

Preclinical → Phase 1 (HER2-Lu); Phase 2 (SN38, cabazitaxel)

Approved products (Illuccix, etc.)

Late-stage clinical

Clinical

Recent Developments

Litigation, regulatory actions, layoffs: * No guidance revisions (company does not guide).

Company Snapshot

$7.8M

Revenue

1996

Founded

Abbotsford, Australia

Headquarters

SWOT Analysis

Strengths

  • Big-pharma validation: Genentech exclusive licence with US$5.5M upfront and up to US$564M milestones plus tiered royalties (ASX, 22 Sept 2025), following ~3 years of joint research.
  • Clinical platform validation: >350 patients treated with DEP® products across three completed Phase 2 programs (FY2024 Annual Report).
  • Regulatory alignment: FDA Type C feedback endorsed the DEP® HER2 first-in-human design and noted potential for Fast Track (ASX, 21 April 2026).
  • Funded runway: ~A$44.5M pro forma cash and runway into FY2028 after a fully underwritten A$32M raise with ~99% take-up (ASX, 15 July and 11 August 2026).
  • Multiple partner shots on goal: Genentech, Radiopharm (up to A$91M), and Petalion (US$25M Medicxi backing, 22.5% equity).
  • Debt-free balance sheet: No borrowings; leases only.

Weaknesses

  • Revenue quality: 69% of FY2026 revenue (A$8.34M of A$12.05M) was a one-off upfront; base revenue ~A$3.7M.
  • Underlying losses widening: Excluding the Genentech upfront, the FY2026 loss was ~A$15.8M versus A$10.0M in FY2025 (derived).
  • Out-licensing delays: DEP® SN38 and DEP® cabazitaxel, top priority for out-licensing in FY2025, remain unpartnered (Q4 FY2025 quarterly; Edison Aug 2026).
  • Concentration risk: Valuation heavily dependent on a single preclinical internal asset (DEP® HER2-Lu).
  • Sub-scale commercial products: VIRALEZE™ and VivaGel® BV generate only low-single-digit millions despite registrations in 30–55+ countries.
  • Small organisation: ~45–50 employees (Revelio estimate) limits parallel program execution.

Opportunities

  • HER2-Lu clinical data (H1 CY2027): Could unlock a large RLT licensing deal given the company-estimated US$17bn addressable market by 2030.
  • Genentech milestones: Development milestones on progression of any nominated product.
  • Radiopharm option exercise: Up to A$91M including payments and royalties.
  • Star Navigator pipeline: Template for additional partner deals with minimal upfront cost.
  • VivaGel® BV European redistribution: Discussions ongoing after Mundipharma exit (Q4 FY2026 quarterly).
  • Accelerated pathways: FDA indicated unmet need in post-HER2-therapy patients, supporting possible Fast Track.

Threats

  • Partner discontinuation: AstraZeneca dropped AZD0466 in July 2023 — the same could happen to Genentech programs.
  • Clinical risk: HER2-Lu has no human data; preclinical radiopharmaceutical biodistribution may not translate.
  • Dilution: The July 2026 offer was priced at a 25% discount; further raises are likely before Phase 2.
  • Competitive intensity in RLT: Well-funded players (Telix, Novartis, others) dominate trial sites and isotope supply.
  • HER2 standard-of-care evolution: Expansion of Enhertu and new HER2 agents may shrink the post-HER2 population or raise efficacy hurdles.
  • Share price volatility: Shares rose >500% in 12 months to August 2026 (Motley Fool), increasing downside sensitivity to delays.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025Q3 FY2025 quarterly: Board and leadership reaffirm strategy; cost control; radio program optimisationStrategic continuity under Maley
Jun 2025Change in substantial holding notices (3–4 June 2025)Register rotation
31 Jul 2025Q4 FY2025 quarterly: cash A$15.4M; customer receipts +A$3.1M; HER2 clinical program planned for 2026Runway concerns building
26 Aug 2025FY2025 results: revenue A$4.9M (+183% underlying), loss A$10.0M (31% better underlying)Base revenue growth
22 Sep 2025Genentech licence: US$5.5M upfront, up to US$564M milestones, tiered royaltiesTransformational validation; share re-rating begins
30 Sep 2025Radiopharm research & option agreement (first Star Navigator deal)Second platform deal in a month
13 Oct 20252025 AGM NoticeGovernance
22 Oct 2025Genentech upfront receivedCash inflow (~A$8.3–8.5M)
14 Nov 20252025 AGM held; resolutions passedGovernance
Jan 2026CEO and VP BD attend JP Morgan Healthcare ConferencePartnering
29 Jan 2026Q2 FY2026 quarterly: receipts A$9.1M; 2026 priorities setExecution
10 Feb 2026Change in substantial holdingRegister rotation
18 Feb 2026H1 FY2026: revenue A$10.8M; half-year profit A$1.37MFirst half-year profit in years
3 Mar 2026New substantial holderInstitutional interest
Mar 2026BIO-Europe partnering; AU targeted-conjugate patent filingBD/IP
7 Apr 2026Application for quotation of securitiesEquity plan vesting/issue
15 Apr 2026New substantial holderInstitutional interest
21 Apr 2026FDA Type C meeting confirms DEP® HER2 first-in-human design; potential Fast Track notedRegulatory de-risking; share +8% on day
29 Apr 2026Q3 FY2026 quarterly: cash A$14.1M; clinical sites selectedTrial readiness
Jun 2026BIO International Convention; UBS and another holder become substantial (17 and 23 June)BD; register
2 Jul 2026DEP® radiopharmaceutical data supports new patent applicationIP
3 Jul 2026Radiopharm milestone triggers A$0.5M option fee; up to A$91M if exercisedPartner progress
7 Jul 2026DEP® HER2-Lu investor webinar: preclinical package, $17bn addressable market claim, Phase 1 designInvestor positioning
15 Jul 2026Q4 FY2026 quarterly (cash A$11.0M) and A$32M fully underwritten 1-for-7.5 entitlement offer at A$0.57 (25% discount)Dilutive but runway-extending; stock fell on the day
17 Jul 2026UBS ceases to be substantial holderRegister
4 Aug 2026Entitlement offer closes—
11 Aug 2026Offer completed, ~99% take-up, 56.1M shares allotted; directors participateStrong shareholder support
19–24 Aug 2026Ceasing/becoming substantial holder noticesRegister
26 Aug 2026FY2026 results and Annual Report; Corporate Governance StatementRevenue +145%, loss −25%
7–29 Sep 2026ASX SMIDcaps Conference presentationInvestor outreach
5–7 Oct 2026Director's interest notice (C. Maley); securities quotation/cessation; change in substantial holdingEquity plan housekeeping
6 Oct 2026Notice of 2026 AGMGovernance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue as reported rose from AUD 9.8 Mn in FY2024 to AUD 12.1 Mn in FY2026.
Starpharma Holdings Limited — Revenue by Segment
Series (AUD Mn)FY2024FY2025FY2026
Total revenue as reported9.84.912.1
One-off licence/settlement income6.608.3
Revenue excluding one-offs3.24.93.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.